ASMB

In the past six months, Assembly Biosciences reported Q4 2025 earnings with positive results, followed by a Q1 2026 loss that missed estimates. The company has a consensus rating of "Moderate Buy" from Wall Street analysts. The company highlighted presentations on positive Phase 1b data for its HSV candidates, ABI-5366 and ABI-1179, at the ESCMID Global 2026 conference. In August 2025, the company completed a $175 million equity raise. ASMB stock has seen a 1.52% increase over the past six months.